UNSPSC 51393310: Mexafylline

This classification denotes a bronchodilator with the molecular formula C14H18N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OTS2XT15W3, chemically known as 2,6(1h,3h)-purinedione, 3-(3-cyclohexen-1-ylmethyl)-1,8-dimethyl- but generally known as mexafylline, which bears US NIH Compound Identifier 3047743. European Medicines Agency schedules Mexafylline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08928MIG.

UNSPSC 51393310 Mexafylline is a Commodity code that captures pharmaceutical products and related health supplies procured by state and local government health agencies. Recent solicitations under this code show state and local buyers purchasing naloxone, drug deactivation systems, and pharmacy benefit program services—products and services supporting community health initiatives, emergency response, and prescription management. The issuing bodies include county health departments and state health and human services commissions. Seminole County, Florida, for instance, recently sought 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, while the Texas Health and Human Services Commission issued a Request for Information to explore direct-to-manufacturer prescription fulfillment models outside traditional pharmacy benefit manager arrangements.

Seminole County, Florida, represents the clearest geographic concentration in recent activity. Seminole County's IFB 60459723LAS, posted June 30, 2026, with a July 26, 2023 response deadline, solicits naloxone and drug deactivation systems for quarterly delivery to the Seminole County Community Health Building in Sanford, with vendors responsible for all shipping costs and required to comply with drug-free workplace, E-Verify, and insurance requirements under a two-year initial term with optional one-year renewal. Texas HHS's RFI HHS0017013, posted April 3, 2026, with the same-day response deadline, seeks vendor capabilities for implementing direct pharmaceutical manufacturer contracting to improve cost management and fulfillment efficiency, indicating early-stage market exploration rather than a formal competitive solicitation. The code shows limited recent activity; opportunities span health supply procurement and pharmacy benefit management but reflect narrow geographic and issuing-body presence.